N/A
N=45
Cutaneous Prostaglandin Application: Nail Growth, Nail Brittleness, and Eye Pressure
Nail Growth Cessation · Intraocular Pressure
Bottom Line
View on ClinicalTrials.gov: NCT02448043 ↗Enrolled (actual)
45
Serious AEs
0.0%
Results posted
Dec 2019
Primary outcome: Primary: Change From Baseline in Nail Length of Hands — 13.49; 15.10; 1.34; 1.51 mm — p=0.532
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Bimatoprost 0.01% (Drug); Placebo: saline (Other)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Northwestern University
- Primary completion
- May 2016
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change From Baseline in Nail Length of Hands |
13.49; 15.10; 1.34; 1.51 | 0.532 |
| PRIMARY Change From Baseline in Nail Length of Digits |
1.58; 1.48; 1.26; 1.02; 0.90; 1.40 | 0.523 |
| PRIMARY Intraocular Pressure at 30 Days of Treatment |
16.42; 13.91; 16.38; 14.0; 16.46; 13.82 | 0.912 |
| PRIMARY Nail Brittleness at 30 Days of Treatment |
2.25; 2.43 | 0.062 |
| SECONDARY Number of Days Until the First Nail Chipped |
8.38; 6.26 | — |
| SECONDARY Change in Skin Pigmentation on Hands |
10; 0; 19; 30; 1; 0 | — |
| SECONDARY Change in Hirsutism on Hands |
0; 0; 34; 34; 0; 0 | — |
Summary
Topical prostaglandin agents are used to help reduce eye pressure in glaucoma patients. Bimatoprost (Lumigan 0.01%) is such an agent (Allergan, Inc.). Several of our patients on bimatoprost and an observational study of patients on bimatoprost in another center reported that fingernails grew longer and became less brittle using the topical eye drops to the eyes. The purpose of the double-blinded study is to determine whether the application of the eye drops directly to the proximal nail fold of one hand using the opposite hand as a control will result in longer nails, less brittle nails, and reduced eye pressures should any of the medication be absorbed into the systemic circulation.
Eligibility Criteria
Inclusion Criteria
- English speaking
- Normotensive or glaucoma suspects on no ocular medications
- No manicure within 2 weeks of the study.
Exclusion Criteria
- Individuals on topical or systemic essential fatty acids (EFA's) in hand lotions, creams, ointments, or medication, or on biotin.
- Digits with signs of nail injury, deformity, or infection.
- Nail biters, nail polishers, artificial nail wear or gels, and nail and trimming and filing until the study endpoint.
- Women of childbearing age who are pregnant or who are trying to become pregnant.
- Individuals with allergies or sensitivity to prostaglandin agents.
Data sourced from ClinicalTrials.gov (NCT02448043). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.